Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Sigyn Therapeutics, Inc. (SIGY) had Return on Tangible Equity of 74.93% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-3.34M |
|
-- |
|
-- |
|
$2.52M |
|
$-2.52M |
|
$-0.82M |
|
$-3.34M |
|
$-3.34M |
|
$-3.34M |
|
$-3.34M |
|
$-3.34M |
|
$-3.34M |
|
$-2.52M |
|
$-2.05M |
|
1.33M |
|
1.33M |
|
$-2.51 |
|
$-2.51 |
|
| Balance Sheet Financials | |
$0.02M |
|
$0.01M |
|
$0.19M |
|
$0.21M |
|
$4.62M |
|
-- |
|
$0.06M |
|
$4.67M |
|
$-4.46M |
|
$-4.46M |
|
$-4.46M |
|
1.60M |
|
| Cash Flow Statement Financials | |
$-0.87M |
|
-- |
|
$0.87M |
|
$0.01M |
|
$0.01M |
|
$0.00M |
|
$0.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.00 |
|
-- |
|
-- |
|
-- |
|
-0.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
74.93% |
|
|
Return on Tangible Equity |
74.93% |
-1562.90% |
|
74.93% |
|
$-2.78 |
|
$-0.65 |
|
$-0.65 |
|